U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06928051) titled 'A Study of S-892216 in Participants With COVID-19' on April 09.
Brief Summary: The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Study Start Date: April 10
Study Type: INTERVENTIONAL
Condition:
COVID-19
Intervention:
DRUG: S-892216
S-892216 will be administered orally as a tablet.
DRUG: Placebo
Placebo will be administered orally as a tablet.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shionogi
Published by HT Digital Content Services with permis...